FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

VANCOUVER, BC, May 11, 2021 -- (Healthcare Sales & Marketing Network) -- Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in t... Biopharmaceuticals, Oncology, FDA Bold Therapeutics, BOLD-100, ruthenium, Gastric Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news